메뉴 건너뛰기




Volumn 61, Issue , 2014, Pages 44-47

Bilateral atypical femoral fractures in a patient prescribed denosumab - A case report

Author keywords

Atypical femoral fracture; Denosumab; Prophylactic nailing; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; DENOSUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHYLPREDNISOLONE; TOCILIZUMAB;

EID: 84893409865     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.12.027     Document Type: Article
Times cited : (71)

References (17)
  • 1
    • 84891034178 scopus 로고    scopus 로고
    • Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research
    • [Epub ahead of print 1/10/2013]
    • Shane E., Burr D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014, [Epub ahead of print 1/10/2013]. 10.1002/jbmr.1998.
    • (2014) J Bone Miner Res
    • Shane, E.1    Burr, D.2
  • 2
    • 84864742990 scopus 로고    scopus 로고
    • Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis
    • Sutton E., Riche D.M. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 2012, 46:1000-1009.
    • (2012) Ann Pharmacother , vol.46 , pp. 1000-1009
    • Sutton, E.1    Riche, D.M.2
  • 3
    • 84991208754 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis
    • Watts B., Bilezikian J.P., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010, (Suppl. 3):1-37.
    • (2010) Endocr Pract , Issue.SUPPL. 3 , pp. 1-37
    • Watts, B.1    Bilezikian, J.P.2
  • 5
    • 34548413629 scopus 로고    scopus 로고
    • Role of RANKL inhibition in osteoporosis
    • McClung M. Role of RANKL inhibition in osteoporosis. Arthritis Res Ther 2007, 9(Suppl. 1):S3.
    • (2007) Arthritis Res Ther , vol.9 , Issue.SUPPL. 1
    • McClung, M.1
  • 7
    • 84155171114 scopus 로고    scopus 로고
    • Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw
    • Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011, 22:2951-2961.
    • (2011) Osteoporos Int , vol.22 , pp. 2951-2961
    • Compston, J.1
  • 8
    • 84878953361 scopus 로고    scopus 로고
    • Proposed pathogenesis for atypical femoral fractures: lessons from materials research
    • Ettinger B., Burr D.B., Ritchie R.O. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 2013, 55:495-500.
    • (2013) Bone , vol.55 , pp. 495-500
    • Ettinger, B.1    Burr, D.B.2    Ritchie, R.O.3
  • 9
    • 84868707203 scopus 로고    scopus 로고
    • Incidence of atypical nontraumatic diaphyseal fractures of the femur
    • Dell R.M., Adams A.L., et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012, 27:2544-2550.
    • (2012) J Bone Miner Res , vol.27 , pp. 2544-2550
    • Dell, R.M.1    Adams, A.L.2
  • 10
    • 84885420745 scopus 로고    scopus 로고
    • Incidence and bone biopsy findings of atypical femoral fractures
    • Tamminen I.S., Yli-Kyyny T., et al. Incidence and bone biopsy findings of atypical femoral fractures. J Bone Miner Metab 2013, 31:585-594.
    • (2013) J Bone Miner Metab , vol.31 , pp. 585-594
    • Tamminen, I.S.1    Yli-Kyyny, T.2
  • 11
    • 84863396445 scopus 로고    scopus 로고
    • Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals
    • Thompson R.N., Phillips J.R., McCauley S.H., Elliott J.R., Moran C.G. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg (Br) 2012, 94:385-390.
    • (2012) J Bone Joint Surg (Br) , vol.94 , pp. 385-390
    • Thompson, R.N.1    Phillips, J.R.2    McCauley, S.H.3    Elliott, J.R.4    Moran, C.G.5
  • 12
    • 69049083492 scopus 로고    scopus 로고
    • Denosumab for prevention of fractures in postmenopausal women with osteoporosis
    • Cummings S.R., San Martin J., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
    • (2009) N Engl J Med , vol.361 , pp. 756-765
    • Cummings, S.R.1    San Martin, J.2
  • 14
    • 84893355169 scopus 로고    scopus 로고
    • [accessed 28/8/2013]
    • MHRA drug analysis print [accessed 28/8/2013]. http://www.mhra.gov.uk/home/groups/public/documents/sentineldocuments/dap_1374834463819.pdf.
    • MHRA drug analysis print
  • 17
    • 0030766092 scopus 로고    scopus 로고
    • Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
    • Khan S.A., Kanis J.A., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12:1700-1707.
    • (1997) J Bone Miner Res , vol.12 , pp. 1700-1707
    • Khan, S.A.1    Kanis, J.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.